Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

aTyr Developing Bi-Specific Platform for tRNA Synthetase-derived Targets

publication date: May 12, 2021

San Diego's aTyr and its Hong Kong subsidiary, Pangu Biopharma, are on track to develop bi-specific antibodies to treat diseases with Neuropilin-2 (NRP2) overexpression, including cancer. Pangu is in the middle of a two year program to develop its bispecific platform with funding from a Hong Kong innovation fund. aTyr’s R&D is based on the extracellular function and signaling pathways of tRNA synthetases, a new area of biology. The company believes bispecific antibodies may be effective in binding targets derived from tRNA synthetases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital